Monte Rosa Therapeutics Ag

Andreas Ritzén

Bernhard Fasching

Alexander Flohr

Laura Ann McAllister

Thomas Ryckmans

Freya Harvey

Vladimiras Oleinikovas

Laura Mcallister

Disclosed herein are compound or pharmaceutically acceptable salts or stereoisomers thereof of formula I: Xis linear or branched Calkyl, Ccycloalkyl, Caryl, 5-10 membered heteroaryl, 4-8 membered heterocycloalkyl, wherein Xis unsubstituted or substituted with one or more of halogen, linear or branched Calkyl, linear or branched Cheteroalkyl, CF, CHF, CMeF, —O—CHF, —O—(CH)—OMe, OCF, Calkylamino, —CN, —N(H)C(O)—Calkyl, —OC(O)—Calkyl, —OC(O)—Calkylamino, —C(O)O—Calkyl, —COOH, —CalkylC(O)OH, —CalkylC(O)O—Calkyl, NH, Calkoxy, Calkylhydroxy, —CHF, —N(H)C(O)—O—Calkyl, and C(OH)(CF); or Xtogether with the N atom of the carbamate forms a 4-8 membered heterocycloalkyl, which is unsubstituted or substituted with one or more of halogen, linear or branched —Calkyl, CF, CHF, CMeF, —O—(CH)—OMe, OCF, OCHF, Calkylamino, —CN, —N(H)C(O)—Calkyl, —OC(O)—Calkyl, —C(O)O—Calkyl, —COOH, —CalkylC(O)OH, —CalkylC(O)O—Calkyl, NH, Calkylhydroxy, and Calkoxy; Xis H, Ccycloalkyl, Caryl, 5-10 membered heteroaryl, 4-8 membered heterocycloalkyl, wherein Xis unsubstituted or substituted with one or more of linear or branched Calkyl, —Calkoxy, NH, NMe, halogen, CF, CHF, CMeF, —O—(CH)—OMe, OCF, OCHF, and Calkylhydroxy; Lis a covalent bond, linear or branched Calkyl; Lis a covalent bond, linear or branched Calkyl; and Lis a covalent bond, linear or branched Calkyl, —O—, or —Calkoxy, wherein linear or branched Calkyl is unsubstituted or substituted with one or more of halogen. Disclosed herein is also their use as modulators of cereblon, methods of preparation of these compounds, compositions comprising these compounds, and methods of using them in the treatment of abnormal cell growth in mammals, especially humans.

Isoindolinone compounds

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrades Proto-oncogene VAV 1 protein (VAV1). The chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having an inflammatory or autoimmune disorder.

Targeted degradation of VAV1

Growing community of inventors

Basel, Switzerland

Andreas Ritzén